摘要
Abstract
Objective To explore the effect of Ambrocol Oral Solution combined with Methylprednisolone Sodium Succinate and Erythromycin in the treatment of children with Mycoplasma pneumonia.Methods A total of 80 children with Mycoplasma pneumonia admitted to Ningjin People's Hospital from December 2022 to December 2023 were selected as the study objects.All the children were divided into two groups using the random number table method,with 40 cases in each group.The control group was treated with Methylprednisolone Sodium Succinate combined with Erythromycin,while the observation group was treated with Ambrocol Oral Solution on the basis of the control group.The clinical efficacy,symptom disappearance time,hospitalization time,inflammatory factor levels,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).The symptom disappearance time and hospitalization time of the observation group were shorter than those of the control group(P<0.05).After treatment,the levels of C-reactive protein and interleukin-6 in the observation group were lower than those in the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The effect of Ambrocol Oral Solution combined with Methylprednisolone Sodium Succinate and Erythromycin in children with Mycoplasma pneumonia is good,which can promote symptom resolution,shorten hospitalization time,and alleviate inflammatory reactions.It is suitable for promotion.关键词
氨溴特罗口服溶液/甲泼尼龙琥珀酸钠/红霉素/儿童支原体肺炎/炎症因子Key words
Ambrocol Oral Solution/Methylprednisolone Sodium Succinate/Erythromycin/Children with Mycoplasma pneumonia/Inflammatory factor分类
医药卫生
